International cohort studies suggest that adding azithromycin to hydroxychloroquine (HCQ) treatment may increase heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length of ECG. Severe adverse events associated with HCQ-azithromycin were compared to HCQ-amoxicillin in rheumatoid arthritis patients aged 18+ and followed up over 30 days. A total of 323,122 and 351,956 users of HCQ-azithromycin and HCQ-amoxicillin were included. When azithromycin was added to HCQ, an increased risk of 30-day cardiovascular mortality (HR2.19), chest pain/angina (HR 1.15), and heart failure (HR 1.22) were observed. HCQ is a drug for malarial and for systemic lupus erythematosus. It recently received Emergency Use Authorization by the FDA for use to treat COVID-19 patients. Source: https://www.medrxiv.org/
Alcohol consumption was independently associated with a substantially higher risk of hepatocellular carcinoma (HCC) among…
Consuming sweets and simple sugars during antibiotic treatment was associated with greater gut microbiome disruption,…
A systematic review of 82 studies found that stroke related to cancer-associated coagulopathy (CAC) is…
Higher consumption of ultra-processed foods (UPFs) was associated with increased risks of multiple chronic diseases…
A meta-analysis of 15 randomized controlled trials involving 4,824 patients with high blood pressure found…
Higher levels of chronic systemic inflammation were associated with smaller left ventricular volumes, compensatory increases…
This website uses cookies.